Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its ...

The stock's fall snapped a four-day winning streak.

Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

Merck (MRK) ended the recent trading session at $80.93, demonstrating a -1.77% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.83%. At the same time, ...

The Business Research Company The Business Research Company's Estrogen Receptor Modulators Global Market Report 2025 – Market Size, Trends, ...

The Business Research Company The Business Research Company's Effective Pain Management Solutions Global Market Report 2025 – Market Size, ...

Summit Therapeutics (NASDAQ:SMMT) shares spiked on Thursday, triggering a trading halt after Bloomberg News reported that ...

LONDON, GREATER LONDON, UNITED KINGDOM, July 3, 2025 /EINPresswire.com/ -- Save 30% On All Global Market Reports With Code ONLINE30 – Stay Informed On Tariff Changes, Macroeconomic Trends, And More.

LONDON, GREATER LONDON, UNITED KINGDOM, July 3, 2025 /EINPresswire.com/ -- Save 30% On All Global Market Reports With Code ONLINE30 – Stay Informed On Tariff Changes, Macroeconomic Trends, And More.

Merck’s stock fell 1.77% to $80.93 while the market gained, despite rising 5.26% over the past month. The company’s upcoming ...

The best-financed lobbyists in the United States are protecting the pharmaceutical sector, but that may change ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as ...